A prospective pilot study revealed that oral administration of phosphatidylcholine for 3 months is beneficial for the management of non-alcoholic fatty liver disease (NAFLD). Ludovico Abenavoli et al. conducted this study to explore the advantages of phosphatidylcholine intervention in NAFLD patients. A total of 30 participants suffering from NAFLD were recruited and administered 300 mg phosphatidylcholine orally with meals (2 capsules at a time, thrice a day) for 3 months.

A comparison of lab and clinical parameters prior to and post-intervention was done. Following administration of  phosphatidylcholine, the level of alanine aminotransferase and aspartate transaminase reduced by 59.6% and 75.4% respectively. Additionally, the level of antioxidant enzymes superoxide dismutase and glutathione peroxidase elevated by 48% and 48.1% respectively after therapy.

To conclude, treatment with phosphatidylcholine yields beneficial outcomes in people diagnosed with NAFLD.